Mark Jason Heath Ellison insider trades: Opiant Pharmaceuticals (OPNT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 27, 2023 | OPNT | ↓ Sell | 610 | $20.26 | $12K | Direct | Jan 31, 2023 (4d) |
| Jan 9, 2023 | OPNT | ↓ Sell | 469 | $20.20 | $9K | Direct | Jan 9, 2023 (0d) |
| Jan 5, 2023 | OPNT | ↓ Sell | 1,806 | $20.20 | $36K | Direct | Jan 5, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mark Jason Heath Ellison's insider trades
Mark Jason Heath Ellison is Chief Development Officer at Opiant Pharmaceuticals (OPNT). Since Jan 5, 2023, Mark has reported no open-market purchases and 3 sales worth $58K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings), shares returned to the company (1 filing), option exercises (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OPNT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.